FDA rule aims to boost quality of safety data from drug trials

09/28/2010 | Wall Street Journal, The

The FDA issued a rule that requires companies testing experimental drugs or medical products to inform the agency within 15 days about serious risks and adverse reactions that arise during clinical studies. The measure, which takes effect March 28, "will expedite FDA's review of critical safety information" and "will better protect people who are enrolled in clinical trials," an FDA official said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA